ChromaDex Corporation — Q1 2022 Form 10-Q
Filing identity: The supplied filing is for ChromaDex Corporation (Nasdaq: CDXC), not a registrant named Niagen Bioscience, Inc. It covers the unaudited quarter ended March 31, 2022; comparisons are with Q1 2021.
Business context
ChromaDex develops and sells nicotinamide riboside (NR), marketed as Niagen. Its businesses include consumer products (primarily Tru Niagen), ingredient sales, and analytical reference standards and services. Consumer products generated most quarterly sales.
Financial highlights
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Net sales | $17.3 million | $14.7 million |
| Gross profit / gross margin | $10.5 million / 61.0% | $9.2 million / 62.9% |
| Operating expenses | $18.3 million | $16.6 million |
| Operating loss | $(7.7) million | $(7.4) million |
| Net loss | $(7.7) million | $(7.4) million |
| Loss per share, basic and diluted | $(0.11) | $(0.12) |
| Cash used in operating activities | $7.2 million | $5.4 million |
- Sales increased 18%. Consumer Products sales rose 20% to $14.9 million, led by e-commerce and higher sales to A.S. Watson. Ingredients sales increased 9% to $1.4 million; analytical standards and services sales decreased 4% to $0.9 million.
- Gross margin declined about 1.9 percentage points. Management cited higher ingredient-segment costs as the business scaled and lower utilization in analytical services.
- Sales and marketing expense rose 32% to $8.2 million, principally from increased consumer marketing. R&D expense rose 37% to $1.1 million. General and administrative expense fell 6% to $8.9 million, mainly because of lower litigation expense, partly offset by severance, restructuring, technology investment, and hiring.
- Cash and restricted cash totaled $21.0 million at quarter-end, down from $28.2 million at December 31, 2021. Current assets were $44.5 million and current liabilities $18.7 million. Accumulated deficit was $176.7 million.
- No borrowings were outstanding on the $10 million Western Alliance Bank credit line. The balance sheet included $4.6 million of operating lease obligations and $17,000 of current finance lease obligations. Inventory purchase commitments were $18.6 million, expected to be paid over approximately one year.
Changes, outlook, and liquidity
Operating cash use increased by $1.8 million year over year, primarily due to higher inventory, lower accounts payable, and the larger net loss, partly offset by increased accrued expenses. Q1 2021 financing had included $33.5 million from stock issuance and option exercises; there were no comparable proceeds in Q1 2022.
Management said existing cash and expected cash generated from sales should support projected operating plans for at least the next 12 months. However, it identified recurring losses, negative operating cash flow, and COVID-19 effects as conditions raising substantial doubt about the ability to meet obligations; after considering plans and resources, management concluded funding was sufficient for that 12-month period. The company may seek additional capital for longer-term plans. Approximately $47.8 million remained available under its $50 million ATM facility at March 31, 2022. No specific financial guidance or quantified sales outlook was provided.
Management cited continuing uncertainty from COVID-19, supply-chain and logistics disruption, labor and input-cost inflation, geopolitical developments, and volatile capital markets. It said inventory was adequate for current demand but warned that higher costs may pressure margins.
Legal, regulatory, and other notable matters
- Elysium litigation: A September 2021 California jury awarded ChromaDex approximately $3.0 million for Elysium’s supply-agreement breaches, while also awarding Elysium $625,000 in refunds or credits and $1.275 million in fraudulent-inducement compensatory and punitive damages. In April 2022, after quarter-end, courts enforced a settlement ChromaDex said resolved the relevant disputes, and the actions were dismissed with prejudice. Settlement terms and financial effects are not clearly provided in the filing text.
- Patent matters: ChromaDex was appealing a ruling that the asserted patents in its Delaware case against Elysium were invalid; the appeal outcome could affect its competitive position. Separate patent challenges by Thorne were ongoing, and related litigation was stayed pending patent review proceedings.
- Other contingencies: ChromaDex recorded an approximately $0.5 million return liability in a customer dispute with Rejuvenation, which sought a refund of approximately $1.6 million. The company also disclosed a disputed $1.6 million sublicense-fee claim from a licensor and stated it did not believe the matter would be material.
- Regulatory and product risk: The company had received FDA/FTC and subsequent FTC warning letters concerning COVID-19-related statements about NR research. It said it removed or requested removal of identified social media posts and disputed that its statements violated applicable law. A product-liability complaint filed in April 2022 was disclosed as a subsequent event; the company had not been served as of May 12, 2022.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level and no material change in internal control over financial reporting occurred during the quarter.
Key facts for investors to verify
- Confirm the registrant and security: this filing is ChromaDex Corporation, ticker CDXC; the supplied company metadata names Niagen Bioscience, Inc.
- Assess whether sales growth can translate into improving margins and reduced operating cash burn, given higher marketing investment and the quarter’s lower gross margin.
- Review cash runway and potential dilution or financing needs, including use of the ATM facility and the conditions on the unused credit line.
- Check the final terms and accounting or cash impact of the Elysium settlement, which was enforced after quarter-end.
- Track patent appeal and inter partes review outcomes, as well as the Rejuvenation, licensor-fee, and regulatory matters.
- Monitor customer concentration: A.S. Watson, a related party, represented 14.8% of Q1 sales and 36.5% of trade receivables at March 31, 2022.